GT Biopharma
GTBP
33 hedge funds and large institutions have $895K invested in GT Biopharma in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
5% more capital invested
Capital invested by funds: $850K → $895K (+$45.2K)
3% more funds holding
Funds holding: 32 → 33 (+1)
0.01% less ownership
Funds ownership: 0.28% → 0.28% (-0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$14.1K |
| 2 |
Renaissance Technologies
New York
|
+$11.7K |
| 3 |
LPL Financial
San Diego,
California
|
+$8.36K |
| 4 |
HF
HRT Financial
New York
|
+$8.23K |
| 5 |
MG
Marex Group
London,
|
+$7.31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFS
Baskin Financial Services
Toronto,
Ontario, Canada
|
-$36K |
| 2 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$12.1K |
| 3 |
Millennium Management
New York
|
-$5.38K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$4.92K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.36K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Osaic Holdings
Scottsdale,
Arizona
| $258 | -$58 | -8 | -19% |
|
|
BBPWM
27
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $77 | – | – | – |
|
|
ASN
28
Advisory Services Network
Atlanta,
Georgia
| $38 | +$37 | +5 | New |
|
|
FRA
29
Front Row Advisors
Tiburon,
California
| $15 | – | – | – |
|
|
RG
30
Retirement Group
San Diego,
California
| $11 | – | – | – |
|
31
JP Morgan Chase
New York
| $4 | -$7 | -1 | -50% |
|
32
Qube Research & Technologies (QRT)
London,
United Kingdom
| $1 | – | – | – |
|
|
BFS
33
Baskin Financial Services
Toronto,
Ontario, Canada
| – | -$36K | -5,045 | Closed |
|
|
CLOS
34
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$12.1K | -1,667 | Closed |
|
|
SPC
35
Sigma Planning Corp
Ann Arbor,
Michigan
| – | -$4.92K | -680 | Closed |
|
|
36
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$3.36K | -465 | Closed |
|
37
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$58 | -8 | -10% |
|
38
Fidelity Investments
Boston,
Massachusetts
| – | -$36 | -5 | Closed |
|
39
Simplex Trading
Chicago,
Illinois
| – | -$37 | -5 | -33% |
|
GTBP Hedge Fund Activity: Q4 2023 in Review
33 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q4 2023, worth a combined $895K — up 5.3% from $850K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GTBP positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $14.1K. The largest seller was Baskin Financial Services, exiting entirely with an estimated $36K sold.
- 33 institutional investors held GT Biopharma (GTBP) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $895K of GT Biopharma stock for Q4 2023, up 5.3% quarter-over-quarter.
- 6 funds opened new GT Biopharma positions in Q4 2023 and 5 closed out, a net change of +1 holder.
- The largest GT Biopharma buyer in Q4 2023 was Citadel Advisors, an estimated $14.1K added.
- The largest GT Biopharma seller in Q4 2023 was Baskin Financial Services, an estimated $36K sold.
Based on aggregated 13F filings for Q4 2023.